摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-噻唑甲酸甲酯 | 59418-09-6

中文名称
4-噻唑甲酸甲酯
中文别名
噻唑-4-甲酸甲酯;4-噻唑羧酸甲酯;噻唑-4-羧酸甲酯
英文名称
methyl thiazole-4-carboxylate
英文别名
methyl 4-thiazolecarboxylate;methyl 1,3-thiazole-4-carboxylate
4-噻唑甲酸甲酯化学式
CAS
59418-09-6
化学式
C5H5NO2S
mdl
——
分子量
143.166
InChiKey
KUWWRNNYEYGSBQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    38-42
  • 沸点:
    129-130 °C(Press: 17 Torr)
  • 密度:
    1.301±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    67.4
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2934100090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:b4428843d806f4ae6d77a149a3cc7037
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl thiazole-4-carboxylate
Synonyms: Thiazole-4-carboxylic acid methyl ester

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl thiazole-4-carboxylate
CAS number: 59418-09-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H5NO2S
Molecular weight: 143.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-噻唑甲酸甲酯 在 sodium hydroxide 作用下, 反应 1.0h, 以96.1%的产率得到噻唑-4-羧酸
    参考文献:
    名称:
    一种噻唑-4-甲酸的制备方法
    摘要:
    本发明公开了一种噻唑‑4‑甲酸的制备方法,可以解决重要传统农药杀菌剂品种之一噻菌灵的老工艺所使用的原料价格相对高昂、收率低的问题,包括以下步骤:首先以L‑半胱氨酸盐酸盐与甲醛、吡啶生成噻唑烷‑4‑甲酸,然后噻唑烷‑4‑甲酸与甲醇、HCl气体反应生成噻唑烷‑4‑甲酸甲酯,噻唑烷‑4‑甲酸甲酯再与乙腈、MnO2反应生成噻唑‑4‑甲酸甲酯,最后噻唑‑4‑甲酸甲酯在氢氧化钠作用下水解得到产品噻唑‑4‑甲酸。该工艺合成路线简单、反应条件温和、成本低、环保安全,具有很好的应用前景,同时也具有较好的社会效益和较高的经济效益。
    公开号:
    CN109574953A
  • 作为产物:
    描述:
    (R)-噻唑烷-4-甲酸甲酯manganese(IV) oxide 作用下, 以 为溶剂, 反应 6.0h, 以60%的产率得到4-噻唑甲酸甲酯
    参考文献:
    名称:
    A FACILE SYNTHETIC APPROACH TO THE FRAGMENT D OF ANTIBIOTIC NOSIHEPTIDE, 2-[1-AMINO-3-CARBOXY-3-HYDROXY-(1S,3S)-PROPYL]-THIAZOLE-4-CARBOXYLIC ACID
    摘要:
    对应于多肽抗生素那西肽片段D的内酰胺是通过氧化相应的噻唑烷-4-羧酸盐来制备的,该噻唑烷-4-羧酸盐是通过2-叠氮基-2,3-二脱氧-d-苏-戊糖醛酸与L-半胱氨酸甲酯缩合获得的。
    DOI:
    10.1246/cl.1982.1975
点击查看最新优质反应信息

文献信息

  • HETEROBICYCLIC COMPOUNDS
    申请人:Amgen Inc.
    公开号:US20130225552A1
    公开(公告)日:2013-08-29
    Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
    Formula (I)的杂环化合物: 或其药用可接受的盐、互变异构体或立体异构体,如规范中所定义,并含有它们的组合物,以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法,如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
  • [EN] 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE ET COMPOSÉS CORRESPONDANTS UTILISÉS EN TANQUE QUE AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) UTILISÉS POUR LE TRAITEMENT DE, P.EX., DE L'ANGIOGENÈSE IMPLIQUÉE OU DE TROUBLES INFLAMMATOIRES
    申请人:IKENA ONCOLOGY INC
    公开号:WO2021127302A1
    公开(公告)日:2021-06-24
    2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).
    2-(1H-吲哚-3-甲酰基)-噻唑-4-羧酰胺衍生物及相应的咪唑、噁唑和噻吩衍生物以及相关化合物作为芳香烃受体(AHR)激动剂,用于治疗涉及血管生成的疾病,例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症,或炎症性疾病。本说明书揭示了示例化合物的合成和表征以及其药理数据(例如第27至32页和59至219页;示例1至8;化合物1-1至1-97;表1-a、2和3)。
  • [EN] DESACETOXYTUBULYSIN H AND ANALOGS THEREOF<br/>[FR] DÉSACÉTOXYTUBULYSINE H ET SES ANALOGUES
    申请人:UNIV RICE WILLIAM M
    公开号:WO2016138288A1
    公开(公告)日:2016-09-01
    In one aspect, the present disclosure provides tubulysin analogs of the formula (I) wherein R1, R2, R3, R4, X1, X2, X3, and A1 are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    在一个方面,本公开提供了公式(I)的tubulysin类似物,其中R1、R2、R3、R4、X1、X2、X3和A1如本文所定义。在另一个方面,本公开还提供了制备本公开化合物的方法。在另一个方面,本公开还提供了药物组合物和使用本公开化合物的方法。
  • Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins
    作者:K. C. Nicolaou、Jun Yin、Debashis Mandal、Rohan D. Erande、Philipp Klahn、Michael Jin、Monette Aujay、Joseph Sandoval、Julia Gavrilyuk、Dionisios Vourloumis
    DOI:10.1021/jacs.5b12557
    日期:2016.2.10
    A streamlined total synthesis of N(14)-desacetoxytubulysin H (Tb1) based on a C-H activation strategy and a short total synthesis of pretubulysin D (PTb-D43) are described. Applications of the developed synthetic strategies and technologies to the synthesis of a series of tubulysin analogues (Tb2-Tb41 and PTb-D42) are also reported. Biological evaluation of the synthesized compounds against an array
    描述了基于 CH 激活策略的 N(14)-去乙酰氧基微管溶素 H (Tb1) 的简化全合成和 pretubulysin D (PTb-D43) 的短全合成。还报告了所开发的合成策略和技术在合成一系列微管溶素类似物(Tb2-Tb41 和 PTb-D42)中的应用。针对一系列癌细胞的合成化合物的生物学评估揭示了许多新的类似物(例如,Tb14),其中一些对某些细胞系具有特殊的效力[例如,Tb32 对 MES SA(子宫肉瘤)细胞系的 IC50 = 12 pM和 2 pM 针对 HEK 293T(人胚胎肾)细胞系],以及一组有价值的构效关系。
  • Mechanism Selection for Regiocontrol in Base-Assisted, Palladium-Catalysed Direct CH Coupling with Halides: First Approach for Oxazole- and Thiazole-4-Carboxylates
    作者:Laure Théveau、Cécile Verrier、Pierrik Lassalas、Thibaut Martin、Georges Dupas、Olivier Querolle、Luc Van Hijfte、Francis Marsais、Christophe Hoarau
    DOI:10.1002/chem.201101615
    日期:2011.12.16
    Both base‐assisted non‐concerted metallation–deprotonation (nCMD) and concerted metallation–deprotonation (CMD) have been identified as two potent operating mechanisms in palladium‐catalysed direct CH coupling of oxazole and thiazole‐4‐carboxylate esters with halides through base‐ and solvent‐effect experiments. Novel C2‐ and C5‐selective CMD direct arylation procedures in oxazole‐ and thiazole‐4‐carboxylate
    两个基地辅助非一致金属化-去质子化(NCMD)和协同金属化-去质子化(CMD)已被确定为在钯催化的直接C上两个有效的操作机构通过与卤化物恶唑的耦合和噻唑-4-羧酸酯ħ碱和溶剂效应实验。然后通过控制电子和空间因素之间的平衡,设计了恶唑和噻唑-4-羧酸酯系列中新颖的C2和C5选择性CMD直接芳基化方法。值得注意的是,钯催化剂和底物之间的电荷相互作用被确定为控制选择性和减少CMD反应中空间因素的影响的参数。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺